Jun 23,2023

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

Medtronic presented new clinical and real-world data on the MiniMed™ 780G system at the 83rd American Diabetes Association Scientific Sessions. The data showed that the system's Meal Detection™ technology supported Time in Range outcomes exceeding consensus guidelines of 70% and helped reduce hyperglycemia. A study also demonstrated that simplified meal announcements using the system helped users maintain glycemic targets and reduce hyperglycemia. Real-world evidence showed strong performance in children, and data on the Medtronic Extended Infusion™ Set demonstrated reduced user burden through less frequent set changes.

CLINICAL STUDY

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

Kakao Healthcare launching Dexcom-powered diabetes management service

Dexcom has partnered with Kakao Healthcare, the digital healthcare division of South Korean company Kakao Corporation, to launch a global digital diabetes management service. The collaboration combines Kakao Healthcare's AI and software technology with Dexcom's continuous glucose monitoring (CGM) devices. The service will be launched in South Korea initially and later expanded to the United States, the Middle East, and Japan. Kakao Healthcare aims to improve public health and contribute to the global expansion of digital healthcare.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 24,2023

THE AMERICAN DIABETES ASSOCIATION AND ABBOTT COLLABORATE ON FIRST-OF-ITS-KIND THERAPEUTIC NUTRITION PROGRAM FOR PEOPLE WITH DIABETES

The American Diabetes Association (ADA) and Abbott are collaborating on a unique therapeutic nutrition program for individuals with diabetes. Abbott is providing a $2.65 million grant over three years to the ADA to support the initiative. The collaboration aims to understand how diabetes technology, such as continuous glucose monitoring (CGM) systems, can assist people in making informed decisions about their diet and activity. Through pilot programs, engagement with healthcare professionals, and roundtable discussions, the partnership seeks to evaluate the effectiveness of CGM systems in personalized therapeutic nutrition.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 20,2023 TOP STORY

Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom

Insulet Corporation has announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System in the United Kingdom for individuals with type 1 diabetes. The system, which integrates with the Dexcom G6 Continuous Glucose Monitoring System, adjusts insulin delivery automatically to help maintain glucose levels. Insulet is working in partnership with the National Health Service (NHS) at all levels to ensure access to Omnipod 5 for people with type 1 diabetes. Insulet plans to release the system in Germany in the fall of 2023.

PRODUCT

#closed loop

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System

Dexcom G6 has become the first and only CGM to connect with the Omnipod® 5 Automated Insulin Delivery (AID) System in the United Kingdom. Dexcom's CGM system provides real-time glucose monitoring and helps protect against high and low glucose levels. By adding another AID product to its CGM ecosystem, Dexcom has both strengthened its position as the world’s most connected CGM, with the Dexcom G6, and offered yet another AID choice to those living with type 1 diabetes in the U.K.

PRODUCT

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023 TOP STORY

Real-World Data Demonstrate the Potential for Rapid and Durable Improvement in Glycemic Control for People with Insulin-requiring Diabetes Using the Bigfoot Unity® System

Bigfoot Biomedical today announced the publication of a six-month retrospective analysis of real-world use data of the Bigfoot Unity® System in the American Diabetes Association's (ADA) journal, Clinical Diabetes. In this initial 58-person cohort, results demonstrate the potential of the Bigfoot Unity System to support rapid and durable improvement in glucose control in people with diabetes who use multiple daily injections of insulin.

CLINICAL STUDY

#cgm

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 15,2023

Nemaura Medical to Exhibit and Provide Live Product Demonstrations of Its Non-invasive Glucose Sensor at the 83rd Scientific Sessions of the American Diabetes Association June 23-26, 2023

Nemaura will showcase its non-invasive glucose sensor at the 83rd Scientific Sessions of the American Diabetes Association. The event will be held from June 23-26, 2023, providing an opportunity for the company to demonstrate its technology for personalized diabetes management.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 13,2023

Medtronic begins U.S. shipments of MiniMed 780G, looks to next-gen CGM

Medtronic said it began shipping its next-generation MiniMed 780G automated insulin delivery system in the U.S. this month. Medtronic’s new artificial pancreas system offers meal detection technology. Additionally, CEO Geoff Martha offered some insights into the Diabetes unit’s product pipeline during the Goldman Sachs global healthcare conference. Medtronic’s diabetes pipeline includes a next-generation continuous glucose monitor (CGM) sensor that is half the size of the company’s present sensor. The medtech giant announced that it received FDA approval for MiniMed 780G with the Guardian 4 sensor in April.

PRODUCT

#insulin pump

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Glucose Monitoring Devices Market Size to Hit US$ 23.19 Billion by 2031

According to a market analysis conducted by Growth Plus Reports, the global glucose monitoring devices market was valued at US$12.72 billion in 2022. It is projected to experience a revenue compound annual growth rate (CAGR) of 7.8% and reach US$23.19 billion by 2031. The market is driven by factors such as the increasing incidence of diabetes and the demand for reliable and user-friendly glucose monitoring solutions, presenting lucrative opportunities for industry players.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023 TOP STORY

Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes

Senseonics, a medical technology company, announced that UnitedHealthcare, the largest health insurance company in the US, will provide coverage for the Eversense E3 CGM System starting July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes. This milestone expands access to over 45 million lives covered by UnitedHealthcare, benefiting people with type 1 and insulin-requiring type 2 diabetes. With this collaboration and extensive coverage, the Eversense CGM System can now reach approximately 300 million covered lives, enhancing diabetes management and improving patient care.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM